Company news

Cynata Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Clears Cynata IND for Phase 2 Trial in GvHD

May 26, 2022

Notice of Allowance for Cynata Chinese Patent

February 27, 2022

Cynata Receives Decision to Grant a Patent in Japan

January 26, 2022

FUJIFILM Cellular Dynamics Executes Manufacturing Agreement

December 28, 2021

Cynata Commences DFU Clinical Trial

December 21, 2021

Site Initiation Visit Completed for CYP DFU Clinical Trial

November 17, 2021

Cynata Receives US$5m Fujifilm Fee

October 17, 2021

DSMB Recommends Continuation of Cynatas MEND Trial

October 7, 2021

Cynata Enters into a New Strategic Partnership with Fujifilm

September 30, 2021

Further Patents for Cynata Unique Cymerus Technology

September 15, 2021

Further Canadian Patent for Cynata

August 30, 2021

Cynata Receives Notice of Allowance from US Patent Office

August 26, 2021

Ethics Approval for Cynatas Clinical Trial in DFU

June 30, 2021

Progress Toward Clinical Trial in Diabetic Foot Ulcers

June 27, 2021

Cynata signs Licence Agreement with TekCyte

June 3, 2021

First Patient Enrolled in Cynata MEND Clinical Trial

May 24, 2021

Cynata Therapeutics Expands MEND clinical trial in COVID-19 and Respiratory Failure

March 29, 2021

Cynata Expands trial in COVID-19 & Respiratory Failure

March 28, 2021

New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs

March 2, 2021

Cynata Therapeutics Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte

March 1, 2021

Cynata Receives $1.39m R&D Tax Incentive Refund

February 21, 2021

Completion of Entitlement Offer and Shortfall Placement

January 17, 2021

Offer Booklet and Entitlement & Acceptance Form

December 21, 2020

Cynata Therapeutics Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline

December 11, 2020

Investor Presentation

December 10, 2020

CYP Closes $15m Institutional Placement to Expand Pipeline

December 10, 2020

Cynata Therapeutics: Phase 3 Osteoarthritis Clinical Trial Commences

November 11, 2020

Phase 3 Osteoarthritis Clinical Trial Commences

November 10, 2020

Potential Utility of Cymerus MSCs in Heart Attack Model

September 23, 2020

Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study

September 8, 2020

Cymerus MSCs Effective in Preclinical Lung Disease Study

September 7, 2020

Patient Enrolment Opens in COVID-19 Clinical Trial

August 24, 2020

Cynata Appoints Dr Geoff Brooke as Chairman

August 18, 2020

Cynata Announces Positive Results from GvHD Trial Follow-up

July 30, 2020

Ethics Approval & Expedited Pathway for Phase 3 OA Trial

June 17, 2020

Block Trade Proceeds to Reduce Director Loans

June 16, 2020

Cynata Successfully Completes Share Purchase Plan

May 26, 2020

Ethics Approval to Commence Clinical Trial in COVID-19

May 7, 2020

Share Purchase Plan Booklet

April 30, 2020

Cynata announces $5.55m capital raising

April 22, 2020

Cynata MSCs beneficial in preclinical ARDS study

April 17, 2020

Cynata provides guidance on planned clinical trials

April 1, 2020

Market Update & Additional A$618k R&D Tax Refund

March 10, 2020

Notice of Allowance from Israel Patent Office

February 6, 2020

December 2019 Quarterly Report

January 29, 2020

Cynata Therapeutics: UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia

January 14, 2020

Cynata Receives UK Regulatory Approval for CLI Trial

January 13, 2020

Cynata Receives $1.892m R&D Tax Incentive Refund

January 6, 2020

Cymerus MSCs Effective in Preclinical Model of Sepsis

December 4, 2019

CYP Files Application to Commence Phase 2 CLI Clinical Trial

November 24, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 39 decks. Every deck is listed under its year.